Long Term DAPT Extension Consideration Tool

Clinical calculation support · Verify results before clinical use

Clinical assessment

Review timing, DAPT tolerance, ischemic features, bleeding concerns, and anticoagulation status.

Decision support · Not a validated score

1. Timing and treatment tolerance

Enter elapsed time since the index ACS event. The tool is intended to support reassessment, not prescribe a duration.

2. Ischemic risk features

Select all that apply. These flags are a checklist, not a validated weighted score.

3. Bleeding risk flags

These prompts do not replace formal ARC-HBR assessment. Some items require clinical details to determine whether a formal criterion is met.

4. Oral anticoagulation

Reset

Clinical context

For ACS patients who are not at high bleeding risk, aspirin plus an oral P2Y12 inhibitor for at least 12 months is the default strategy. Beyond 12 months, extension may be considered in selected patients after weighing recurrent ischemic events against bleeding and incorporating patient preference.

How to interpret this checklist

  • Use the result to prompt a structured clinical review, not to mandate continuation or discontinuation.
  • Prior MI, multivessel disease, diabetes, CKD, LV dysfunction, PAD, and prior stent thrombosis may inform ischemic risk, but this tool does not assign validated weights.
  • Bleeding flags are intentionally prompts only. Confirm formal ARC-HBR criteria using complete clinical and laboratory information; consider validated tools such as the DAPT score or PRECISE-DAPT when appropriate.
  • When long-term oral anticoagulation is indicated, avoid treating prolonged triple therapy as the default; antithrombotic strategy depends on time from PCI/ACS and individual thrombotic risk.

Important limitation

The checklist categories and thresholds are pragmatic and have not been prospectively validated. It does not estimate absolute risk, NNT, NNH, or treatment effect and does not replace cardiology review or local guidelines.

Selected references

2025 ACC/AHA/ACEP/NAEMSP/SCAI ACS Guideline
Rao SV, et al. J Am Coll Cardiol. 2025;85:2135–2237. doi:10.1016/j.jacc.2024.11.009
2023 AHA/ACC Chronic Coronary Disease Guideline
Virani SS, et al. J Am Coll Cardiol. 2023. doi:10.1016/j.jacc.2023.04.003
DAPT Study
Mauri L, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–2166. doi:10.1056/NEJMoa1409312
Clinical disclaimer: This educational decision-support tool is intended for healthcare professionals. It does not replace clinical judgment, a complete review of the patient record, shared decision-making, or current local and professional guidelines. Do not make antithrombotic changes solely on the basis of this output.